Microdoses (mg) as a supplement; very far from the pharmacological dose.
Lithium at very low doses (orotate) is promoted for mood and as a neuroprotector; ecological studies associate more natural lithium in water with less suicide and perhaps less dementia. The evidence for the SUPPLEMENT is very weak. (Prescription lithium does treat bipolar disorder, always under medical supervision.)
⏱ 3 min read
Lithium orotate is a lithium salt (the chemical form of the lithium cation bound to the anion of orotic acid) marketed as a nutritional supplement in some countries, distinct from the pharmaceutical lithium carbonate and citrate used as psychiatric medications at high doses (300-1,800 mg/day) for bipolar disorder and severe mood disorders; lithium orotate as a supplement is typically used at “microdoses” (5-20 mg of elemental lithium, equivalent to 130-520 mg of lithium orotate), figures several tens of times lower than pharmacological ones, on the theoretical premise of providing lithium's neuroprotective and mood-modulating properties without the serious clinical risks of standard therapeutic doses.
Unlike most nutritional minerals, lithium is not formally recognized as essential for humans, but there is growing epidemiological evidence suggesting a beneficial role of very low intakes (micrograms to milligrams per day from natural sources such as lithium-containing mineral waters or certain plants): population studies correlate low lithium levels in drinking water with a higher incidence of suicide, violent crime, and mood disorders, while regions with naturally lithium-richer water show significant reductions in these indicators, an observation that has fueled clinical interest in nutritional microdoses as a preventive intervention.
In mild depression, irritability, anxiety, and emotional lability, several small studies and integrative clinical observation suggest moderate benefits with lithium orotate microdoses of 5-20 mg/day for weeks to months; rigorous clinical data are limited, but the favorable tolerability profile and low cost make it an option in integrative and nutritional psychiatry, especially as an adjunct or in conditions where standard pharmacology is not wanted or needed.
Mechanistically, lithium has documented neuroprotective effects at therapeutic doses (increased BDNF, GSK-3 inhibition, modulation of neuronal autophagy, stabilization of neuronal membranes); although the clinical relevance of these mechanisms at nutritional microdoses has not been demonstrated, there is a reasonable theoretical basis to hypothesize long-term beneficial effects on cognitive function and neurodegeneration prevention.
Typical supplemental doses are 5-20 mg of elemental lithium daily (equivalent to 130-520 mg of lithium orotate depending on the product), taken once a day with or without food; commercial products in countries where it is legally available as a supplement vary in concentration, and it is worth reading the label carefully to distinguish between "milligrams of lithium orotate" (the whole salt) and "milligrams of elemental lithium" (the actual amount of the active cation); the effect on mood appears gradually and requires at least 2-4 weeks for clinical evaluation.
Although microdoses have a significantly more favorable safety profile than pharmacological therapeutic doses, there are important clinical considerations: people with serious kidney disease should avoid lithium (even at microdoses) because of renal excretion; those taking drugs that affect kidney function or fluid and electrolyte balance (diuretics, ACE inhibitors, ARBs, chronic NSAIDs) should use caution; people with hypothyroidism should monitor thyroid function because even microdoses may modulate thyroid function with prolonged use; those who take very high doses of caffeine may experience interference with the renal excretion of lithium; people with bipolar disorder who are being treated with pharmaceutical lithium should not add lithium orotate supplements without psychiatric supervision; in pregnancy, lithium (even at microdoses) is discouraged because of data on cardiac teratogenicity at high doses and the precautionary principle; during breastfeeding, lithium passes into breast milk; adverse effects at microdoses are rare and mild (mild digestive discomfort, occasionally fatigue at the start), but monitoring is prudent with prolonged use; in countries where lithium orotate is not approved as a supplement (Spain and the EU in general), its legal sale is ambiguous, and it is advisable to verify local availability and regulation before purchasing products; overall, the reasonable clinical position is to regard lithium orotate as a supplement with a low profile of robust clinical evidence but with a solid theoretical basis and an acceptable safety profile at the recommended microdoses, preferably used under professional supervision.
Information, not medical advice. Scientific evidence reflects the quality of the studies.